Eltrombopag Olamine

Eltrombopag Olamine is a small molecule thrombopoietin (TPO) receptor agonist that interacts with the transmembrane domain of the human TPO-receptor, initiating signaling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, leading to increased platelet production. Used for persistent or chronic ITP, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. Initial dose: 50 mg once daily, adjusted based on platelet counts. Take on empty stomach, at least 2 hours before or 4 hours after calcium-rich foods or polyvalent cation-containing products. Common side effects include nausea, diarrhea, fatigue, headache and elevated liver enzymes.

• Thrombocytopenia in persistent or chronic immune thrombocytopenia
• Thrombocytopenia in hepatitis C infection
• Severe aplastic anemia

Eltrombopag Olamine is a small molecule thrombopoietin (TPO) receptor agonist. It interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells, finally leading to increased platelet production.

Eltrombopag interacts with the human TPO receptor transmembrane domain and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, increasing platelet production.

Adult Dose:

• Chronic ITP: 50 mg once daily, adjust to maintain platelet count ≥50×109/L. Max: 75 mg/day.
• Chronic hepatitis C: 50 mg once daily, max 100 mg/day.
• Severe aplastic anemia: 50 mg once daily, adjust to maintain platelet count ≥50×109/L. Max: 150 mg/day.

Child Dose (6 years+): 50 mg once daily. (1-5 years: 25 mg once daily).

Oral tablet. Take on empty stomach (1 hour before or 2 hours after meals). Take at least 2 hours before or 4 hours after calcium-rich foods or polyvalent cation-containing products. Swallow whole. Do not chew, crush or break.

If you miss a dose of Eltrombopag Olamine, skip it and continue with your normal schedule. Do not double the dose.

Common Side Effects:

• Nausea
• Diarrhea
• Upper respiratory tract infection
• Vomiting
• Increased liver enzymes
• Muscle pain
• Urinary tract infection
• Anemia
• Pyrexia
• Cough
• Fatigue
• Headache

• Eltrombopag Olamine can cause dizziness and make you less alert, affecting driving ability.
• Take on empty stomach (1 hour before or 2 hours after meals).
• Take at least 2 hours before or 4 hours after dairy products and calcium-fortified juices.
• Monitor platelet counts regularly.
• Monitor liver function.

• Severe hepatic impairment
• Hypersensitivity to eltrombopag or any excipient

Increased plasma Cmax & AUC of HMG-CoA reductase inhibitors. Caution with methotrexate, topotecan. Increased concentration with fluvoxamine; decreased with rifampicin & lopinavir/ritonavir. Reduced absorption by antacids, dairy products & polyvalent cation-containing products (e.g., Fe, Ca, Mg, Al, Se, Zn).

It is not known whether it is safe to consume alcohol with Eltrombopag Olamine. Please consult your doctor.

Eltrombopag Olamine may be unsafe during pregnancy. Animal studies have shown harmful effects. Doctor will weigh benefits and risks.

Eltrombopag Olamine is probably unsafe during breastfeeding. Limited human data suggests drug may pass into breastmilk and harm the baby.

Safety and efficacy in pediatric patients below 1 year with ITP not established. Safety in hepatitis C and severe aplastic anemia not established.

Limited information available regarding dose adjustment for elderly patients.

Renal impairment: Safe in kidney disease. No dose adjustment needed.

Hepatic impairment: Use with caution. Dose adjustment may be needed.

Overdose may cause excessive platelet count increase leading to thrombotic or thromboembolic complications. Consider oral administration of metal cation-containing preparation (calcium, aluminium or magnesium) to chelate eltrombopag and limit absorption.

Store below 25°C in a cool, dry place protected from light. Keep out of reach of children.

Eltrombopag Olamine